Management of multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma with rhenium-188-HDD-lipiodol
![Thumbnail](/bitstream/handle/11295/44628/Abstract.PDF.jpg?sequence=4&isAllowed=y)
View/ Open
Date
2006Author
Kumar, A
Bal, C
Srivastava, DN
Thulkar, SP
Sharma, S
Acharya, KS
Duttagupta, S
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
We tried to evaluate the role of dosimetry-guided transarterial radionuclide therapy (TART) with rhenium-188 (Re-188)-4-hexadecyl 1-2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol (HDD)-lipiodol in a patient with multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma (HCC). The dosimetry helped in delivering the maximum possible activity of Re-188, thus the radiation-absorbed dose, safely to the tumour without jeopardizing other organs. There was no procedure-related complication and the patient tolerated therapy well with no adverse effects. The lesions were completely ablated with a single dose of Re-188 and the patient has been disease free for the past 18 months. TART with Re-188-HDD-lipiodol appears to be a promising therapeutic option in patients with HCC who experience recurrence after percutaneous ablative therapy.
URI
http://profiles.uonbi.ac.ke/sacharya/publications/kumar-bal-c-srivastava-dn-thulkar-sp-sharma-s-acharya-sk-duttagupta-smanagemenhttp://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/44628
Citation
KIRTDA, DRACHARYAS. 2006. Kumar A, Bal C, Srivastava DN, Thulkar SP, Sharma S, Acharya SK, Duttagupta S.Management of multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma with rhenium-188-HDD-lipiodol.Eur J Gastroenterol Hepatol. 2006 Feb;18Publisher
Department of Medicine, College of Health Sciences, University of Nairobi
Collections
- Faculty of Health Sciences (FHS) [10378]